The patent application relates to the treatment of headaches, focusing on protecting the company's product Ozilia Migraine. The granting of the application means that a fourth U.S. patent is added to a growing patent family focused on headache treatment, which the company has been building since 2011.

"One of the three cornerstones of our strategic efforts to build shareholder value is to fulfill our patent strategy. The intellectual property defense of our technology to support our ongoing business development is an essential part of what we consider core values in the company," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical today holds 79 patents across 32 countries and 9 patent families, covering various aspects of the company’s treatment technologies. The patent families deal with various aspects of Chordate’s technology and are designed to provide the best possible protection for the inventions that is the basis for the company’s products.

"LSX brings together potential investors in biotech, medtech, and healthtech from around the world in one place. It's a very fitting forum for us to present Ozilia as the latest development in migraine treatment," says Anders Weilandt, CEO of Chordate.

This year's edition of LSX World Congress is the tenth in its series. The purpose of the event is to connect capital with innovative developments to help create tomorrow's health solutions that can benefit more people.

"We already have the scientific evidence in place and are beginning to show proof of concept in several of our focus markets. The next step in the company's strategy is to find a buyer for the company. At LSX World Congress and other similar events we participate in during the spring, we find precisely the right target audience for us."

Read more about LSX World Congress

"It's an excellent opportunity for us to introduce Ozilia and inform a large number of migraine and headache specialists from three significant European markets all at once," says Anders Weilant, CEO of Chordate.

The congress will bring together headache specialists and neurologists to discuss and present the latest developments in migraine treatment, with neuromodulation being one of the topics on the agenda.

"In addition to raising awareness of Ozilia among potential investors and buyers of the company, it's important that we continue to engage with the profession in various markets. Interest in neuromodulation as a treatment technique for migraine among specialists and neurologists is growing, and Ozilia is a unique and new treatment option that an increasing number is evaluating."

Learn more about the congress

"Our participation at Feminvest aligns with our increasing focus on raising awareness about the company and Ozilia across various industry and investor segments. Feminvest has a strong network of investors focused specifically on femtech and life science, where Ozilia fits into both areas," says Caroline Lundgren Brandberg, non-executive Director of Chordate Medical.

Feminvest is an acceleration network for female ownership through education, as well as an investment venture. It is currently the largest hub for female investors and entrepreneurs in the Nordic region with almost 47,000 subscribers. Feminvest also operates a network of 300 female angel investors. For Chordate Medical, the investor event in Oslo on April 25 is one of several meeting points during the spring. On the same date, the company's CEO, Anders Weilandt, will be in Switzerland showcasing Ozilia at a joint congress for specialist associations from Switzerland, Germany, and Austria.

"As Ozilia gains increasing acceptance and success in our target markets, it is natural for us to expand efforts to raise awareness for Ozilia among potential investors and buyers of the company," says Anders Weilandt, CEO of Chordate.

Caroline Lundgren Brandberg, MSc. Eng. Physics, eMBA, has been a board member of Chordate Medical since 2021. Caroline is the Global Sales Director at climate tech company Deedster and has previously worked internationally for Ericsson in various leadership roles with a focus on sales and marketing. She also holds several board and advisory board positions, including at Stockholm University.

Read more about Feminvest Fearless